Fintel reports that on February 5, 2025, Leerink Partners upgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN) from Market Perform to Outperform. Analyst Price Forecast Suggests 42.56% ...

Michael Fanone, a former Washington, D.C., police officer who was attacked during the Jan. 6, 2021, riot at the Capitol, cursed out Stewart Rhodes, the founder of the anti-government group the Oath ...

Regeneron and Society for Science selected The Frazer School senior Sophia Rong as a finalist in the Regeneron Science Talent Search 2025. Rong was the only ...

The Domo platform is designed to engage people (especially those without data science backgrounds), helping them learn and progress in making data-driven decisions. 4. Conversational AI for ...

Trevogrumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Obesity. According to GlobalData, Phase II drugs for Obesity have a 29% phase transition success ...

With a market cap of $77.3 billion, Regeneron Pharmaceuticals, Inc. (REGN) is a leading biotechnology company dedicated to discovering, developing, and commercializing innovative treatments for a ...

As of December 23, 2024, the average one-year price target for Regeneron Pharmaceuticals is $1,093.96/share. The forecasts range from a low of $570.65 to a high of $1,291.50.

Regeneron Pharmaceuticals Inc.'s executives and board members overstated its key eye treatment’s average selling price, prompting a Department of Justice enforcement action and exposing the drugmaker ...

Your biospecimen will be sent to the Regeneron Genetics Center for genetic sequencing, then stored for future analysis. With something as sacred as your genetic material in its hands, Truveta and ...

© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

Regeneron stock has trended bearishly since August, but growth in LIBTAYO and DUPIXENT offers a promising outlook, prompting a BUY rating. EYLEA HD's success mitigates biosimilar competition ...